J.B. Chemicals & Pharmaceuticals Ltd Q2 FY26 – From Rantac to Romance with Torrent, ₹1,085 Cr Sales and an 8% Growth Pill That’s Actually Working
1. At a Glance
J.B. Chemicals & Pharmaceuticals Ltd (JBCPL) just reported Q2 FY26 numbers that made even the auditors crack a smile. Revenue stood tall at ₹1,085 crore, up 8% YoY, while net profit rose 19% YoY to ₹208 crore — all with a P/E of 39.9 that screams, “I’m not cheap, but I’m worth it.” The company’s market cap now sits at a juicy ₹28,663 crore, with an ROE of 20.1%, ROCE of 25.8%, and a debt of barely ₹19 crore — practically pocket change in pharma land. The dividend yield of 0.85% won’t make you rich, but hey, it’s better than most savings accounts where you also lose your peace of mind.
The highlight, though, wasn’t just the quarter’s numbers — it’s the Torrent Pharma acquisition saga. With Torrent shelling out ₹11,917 crore for a 46.39% stake and offering ₹1,639.18 per share for another 26% open offer, J.B. has become the most sought-after date in Indian pharma.
Who knew the creators of Rantac, Nicardia, and Cilacar would be the subject of one of India’s biggest pharma takeovers? Welcome to the desi version of “Merger and Medication.”
2. Introduction – The Legacy of the Lozenges Lord
If there were a Hall of Fame for Indian mid-cap pharma success stories, J.B. Chemicals would be right up there with its Daman lozenge factory framed in gold.
Founded in 1976, back when Bollywood still believed in double roles and villains with scars, JBCPL quietly built a brand portfolio that every household medicine cabinet knows by heart — Rantac (acid reflux), Metrogyl (the ultimate stomach fixer), and Nicardia (heart’s BFF).
It’s the kind of company that never chased drama, yet now finds itself in one — with Torrent Pharma, the Gujarat-based pharma giant, swooping in for a ₹25,689 crore merger romance. That’s right: from making ₹46 crore EPS tablets to swallowing mergers worth ₹25,000 crore. This is pharma’s own Kabhi Acquisition Kabhi Merger.
What’s more, it’s not just an Indian story. J.B. exports to over 50 countries, has 8 global manufacturing facilities, and boasts 40+ international regulatory accreditations. From Russia to South Africa, its tablets travel farther than your last vacation.
And for FY24, domestic formulations made up 55% of revenues, while exports brought in another 30%, proving that while the world might argue, J.B. just prescribes.
But before we overdose on admiration, let’s swallow some data with water.
3. Business Model – WTF Do They Even Do?
Alright, pharma jargon alert. But let’s simplify.
J.B. Chemicals makes and sells formulations (tablets, lozenges, ointments, syrups, and everything your chemist mumbles about). The business is split across four lines:
Domestic formulations (55%) – Think chronic therapies like hypertension and cardiac, starring Cilacar and Nicardia.
Export formulations (30%) – Russia, CIS, South Africa, and Latin America are their biggest fans.
Contract manufacturing (13%) – They make pills for others — the unsung ghostwriter of global pharma.
APIs (2%) – The chemical backbone that keeps it all together.
Now, here’s the kicker: they’ve inked a Trademark License Agreement with Novartis for a portfolio of ophthalmology brands, effective January 2027, for a whopping USD 116 million. That’s roughly ₹960 crore in eye drops — talk about liquid gold!
They’re also paying ₹125 crore for exclusive promotion rights till 2026. So yes, by FY27, JB will officially be selling you relief for your eyes after staring at your screen too long.
Eight manufacturing facilities — Daman, Ankleshwar, and Panoli — keep this pharmaceutical machinery running. And with over 40 regulatory accreditations, it’s clear JB’s compliance team doesn’t sleep much.
4. Financials Overview – The Pill Pops with Profit
The margins keep improving like a doctor’s handwriting after digital prescriptions. Operating margins stood near 29%, proving they know how to price pain relief profitably. PAT margin is a healthy ~19%, meaning every ₹100 tablet leaves ₹19 profit after tax — not bad for a company that doesn’t even sell paracetamol.
5. Valuation Discussion – The Fair Value Range (Educational Purpose Only)
Method 1: P/E Approach Industry P/E = 31.6 JB’s P/E = 39.9 Annualised EPS = ₹53.08 So, fair value range = ₹53.08 × (30–35) = ₹1,590 – ₹1,858
Method 2: EV/EBITDA Approach EV/EBITDA = 25× currently EBITDA (FY25 TTM) = ₹1,091 Cr If we assume a normalized 20–22× multiple → fair EV = ₹21,820–₹24,002 Cr Subtract debt (₹19 Cr), add cash → Market cap range ≈ ₹21,800–₹24,000 Cr → per share ≈ ₹1,380–₹1,520
Method 3: DCF (simplified) Assuming 17% CAGR PAT growth for 5 years, discounting at 12%, fair range = ₹1,600–₹1,850
💡 Educational Disclaimer: This fair value range is for educational purposes only and not investment advice. (If you lose money, blame the market, not the maths.)
6. What’s Cooking – News, Triggers, Drama
You’d think pharma is boring. Nope — JB is now in the middle of a Bollywood-grade M&A drama.
Torrent Pharma Deal: Torrent is acquiring 46.39% stake for ₹11,917 crore, and has launched an open
